For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
VP, Real-World Evidence
As Vice President for Parexel’s Real-World Evidence Services, Kim helps clients develop strategies which align to their business plan. With over 20 years of experience in clinical research, Kim has extensive knowledge of a variety of therapeutic areas in both Phase IIIb and IV studies and risk management programs.
Kim has been responsible for designing and delivering several programs which have been developed to meet FDA and EMEA mandates for post approval regulatory commitments and for risk assessment and risk minimization. She recently provided oversight for a large cardiovascular outcomes trial consisting of 250 sites and 9,000 patients.
Prior to joining Parexel, Kimberly served as Senior Director for Late Phase Services for PRA Health Sciences. She previously served as Director of Consulting Practice Operations for United BioSource Corporation (UBC), where she was responsible for the business operations of the Epidemiology and Risk Management (ERM) Consulting Practice.
Kim holds a B.S. in Biology from Fairfield University Academic Scholarship. She has also delivered several thought leadership presentations and publications on Real-World Evidence.